Gut Microbiota Alterations Associated with Viral Activity in Chronic Hepatitis B

Read full text Summarise with VIRAT
Authors: Paola Nasta, Marco Di Gregorio, Monica Zaia, Giampiero Carosi
Cited by: 0
References: 39

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: The gut–liver axis plays a pivotal role in chronic liver diseases, and increasing evidence links gut microbiota dysbiosis to disease progression in chronic hepatitis B (CHB). However, data comparing microbiota features between patients with active and inactive HBV infection remain limited.Methods: We performed a retrospective analysis of gut microbiota composition and functional potential in patients with chronic HBV infection, stratified according to viral activity as defined by current EASL guidelines. Microbial diversity, taxonomic composition, enterotypes, pathobiont prevalence, and predicted metabolic pathways were compared between active and inactive HBV infection.Results: Patients with active HBV infection exhibited significantly reduced microbial α-diversity, lower phylogenetic diversity, and decreased evenness compared with inactive carriers, despite virological suppression under antiviral therapy. Active HBV was associated with Prevotella-dominated enterotypes, expansion of pathobionts (Escherichia coli, Klebsiella pneumoniae, Bacteroides fragilis), and depletion of beneficial symbionts, particularly short-chain fatty acid– and indole-producing taxa, including Faecalibacterium prausnitzii, Roseburia intestinalis, Blautia wexlerae, and Alistipes spp. Functional profiling revealed reduced production of butyrate, propionate, acetate, and indole derivatives, alongside increased synthesis of ethanol, secondary bile acids, and lipopolysaccharides.Conclusion: Active CHB is characterized by a distinct dysbiotic and pro-inflammatory gut microbiota profile that persists despite effective antiviral therapy. These findings support a contributory role of gut microbiota in immune dysregulation and disease activity in CHB and provide a rationale for microbiota-targeted interventions as complementary therapeutic strategies.

Fields of Study & Subjects

Gut microbiota and health Hepatitis B Virus Studies Oral microbiology and periodontitis research

Publication details

Journal / source
Archives of Case Reports
Pages
021–029
Publication date
24 March 2026
Language
EN